IL284779A - Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase - Google Patents

Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Info

Publication number
IL284779A
IL284779A IL284779A IL28477921A IL284779A IL 284779 A IL284779 A IL 284779A IL 284779 A IL284779 A IL 284779A IL 28477921 A IL28477921 A IL 28477921A IL 284779 A IL284779 A IL 284779A
Authority
IL
Israel
Prior art keywords
gout
proton
inhibitor
treatment
methods
Prior art date
Application number
IL284779A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL284779A publication Critical patent/IL284779A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL284779A 2019-01-22 2021-07-12 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase IL284779A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US201962913270P 2019-10-10 2019-10-10
PCT/US2020/014346 WO2020154252A1 (en) 2019-01-22 2020-01-21 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
IL284779A true IL284779A (en) 2021-08-31

Family

ID=69726724

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284779A IL284779A (en) 2019-01-22 2021-07-12 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Country Status (11)

Country Link
US (1) US12544372B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914250A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022523018A (cg-RX-API-DMAC7.html)
KR (1) KR20210119457A (cg-RX-API-DMAC7.html)
CN (3) CN113423401A (cg-RX-API-DMAC7.html)
AU (2) AU2020213265B2 (cg-RX-API-DMAC7.html)
CA (1) CA3125236A1 (cg-RX-API-DMAC7.html)
IL (1) IL284779A (cg-RX-API-DMAC7.html)
MX (2) MX2021008696A (cg-RX-API-DMAC7.html)
TW (1) TW202042815A (cg-RX-API-DMAC7.html)
WO (1) WO2020154252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI907406B (zh) 2020-04-03 2025-12-11 美商建南德克公司 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
WO2018175863A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. Methods of treating autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
CN113423401A (zh) 2021-09-21
AU2025201888A1 (en) 2025-04-03
EP3914250A1 (en) 2021-12-01
JP2026041743A (ja) 2026-03-10
AU2020213265B2 (en) 2025-01-16
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25
KR20210119457A (ko) 2021-10-05
CA3125236A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
MX2025013950A (es) 2026-03-02
WO2020154252A1 (en) 2020-07-30
AU2020213265A1 (en) 2021-07-22
TW202042815A (zh) 2020-12-01
JP2022523018A (ja) 2022-04-21
MX2021008696A (es) 2021-08-19
US20220047588A1 (en) 2022-02-17
US12544372B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
DK3788047T3 (da) Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
IL281225A (en) Improved support bases, adapters for them and systems and methods related to them
IL280319B1 (en) Foundations with screw supports and related systems, methods and machines
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
ZA201903672B (en) Asset transfer method and apparatus, and electronic device
MA51871A (fr) Combinaison d'une thérapie cellulaire et d'un composé immunomodulateur
EP3509948A4 (en) METHODS AND SYSTEMS FOR DAMPING VIBRATION OF A PAYLOAD
EP3941922A4 (en) RAF KINASE INHIBITORS
EP3445764A4 (en) DEGRADATION OF CYCLINE-DEPENDENT KINASE 8 (CDK8) BY CONJUGATING CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF
IL281060A (en) Systems and methods of optimal metrology guidance
EP3360078A4 (en) CHARACTERIZATION OF DYNAMIC STATISTICAL SYSTEMS
SG11202103142TA (en) Heterocyclic kinase inhibitors and uses thereof
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
IL284636A (en) Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefore
EP3573619A4 (en) THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
DK3465202T3 (da) Massespektrometrifremgangsmåde til detektering og kvantitering af metabolitter
DK3404258T3 (da) Systemer og fremgangsmåder til stabilisering af effektgenerering
EP3595665A4 (en) DUAL MAGL AND FAAH INHIBITORS
EP3765008A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
IL285893A (en) Scalable floating micro-aeration unit, devices and methods
LT3972603T (lt) Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių
PL3396024T3 (pl) Urządzenie elektrochemiczne i sposób eksploatacji urządzenia elektrochemicznego
DK3170784T3 (da) Fremgangsmåde til drift af et ankerspil og ankerspil
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
PL3522324T3 (pl) Sposób i układ do zarządzania obciążeniem urządzeń elektrycznych